查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1978779

特發性肺纖維化市場：按治療分類、給藥途徑、通路和最終用戶分類 - 全球預測 2026-2032 年

Idiopathic Pulmonary Fibrosis Market by Therapeutic Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，特發性肺纖維化市場價值將達到 41.9 億美元，到 2026 年將成長至 44.2 億美元，到 2032 年將達到 61.9 億美元，年複合成長率為 5.71%。

主要市場統計數據
基準年 2025 41.9億美元
預計年份：2026年 44.2億美元
預測年份 2032 61.9億美元
複合年成長率 (%) 5.71%

特發性肺纖維化的臨床和操作介紹：重點關注診斷的複雜性、治療進展和不斷發展的護理路徑。

特發性肺纖維化 (IPF) 是一種持續且複雜的臨床挑戰，需要在診斷、治療和護理的各個方面協調推進。其症狀通常特異性，且與其他慢性呼吸系統疾病的症狀重疊，給臨床醫生早期發現疾病帶來了障礙。同時，確診需要高解析度影像學檢查、肺功能檢查以及多學科會診。這些診斷方面的現實情況會延遲疾病修正治療的啟動，並使病程管理更加複雜，凸顯了建立更清晰的臨床路徑和改善診斷資源獲取途徑的迫切需求。

變革性的科學、監管和交付模式的改變正在重塑特發性肺纖維化患者的治療和護理的發展。

由於科學、監管和給藥模式的動態動態，特發性肺纖維化 (IPF) 的治療和護理格局正在經歷變革性變化。分子生物學和轉化研究的進步加深了我們對纖維化路徑的理解，為探索補充或增強現有抗纖維化策略的新作用機制開闢了可能性。同時，監管機構也越來越接受適應性方法和基於真實世界證據的方法，這些方法能夠以令人信服的機制證據縮短藥物研發週期。這也正在改變申辦者對候選藥物的優先排序和臨床實驗方案的設計方式。

對 2025 年美國關稅調整對供應鏈、價格波動以及 IPF 患者獲得治療的累積影響進行全面分析。

2025年的貿易政策趨勢和關稅調整為IPF供應鏈、藥品原料採購以及治療藥物和醫療設備的跨境分銷帶來了複雜的局面。累積的關稅措施可能會增加從世界各地採購的藥品活性成分和輔料的投入成本，迫使製造商重新評估其供應商組合和原料籌資策略。因此，企業可能會採取雙重採購、近岸外包或垂直整合等策略，以確保供應的連續性並降低地緣政治波動帶來的風險。

從治療領域、給藥途徑、分銷管道和醫療保健環境等方面的差異出發，制定詳細的細分觀點，從而推動商業和臨床策略的發展。

細分市場層面的差異化是特發性肺纖維化（IPF）相關人員進行策略決策的基礎，需要對治療領域、給藥途徑、分銷網路和終端用戶環境有深入的了解。基於治療領域，我們分析了抗纖維化藥物和免疫抑制劑。抗纖維化藥物進一步細分為尼達尼布和Pirfenidone，免疫抑制劑進一步細分為糖皮質激素和免疫調節劑。糖皮質激素包括Methylprednisolone和潑尼松，而免疫調節劑包括Azathioprine和Mycophenolate Mofetil。每種藥物都有不同的臨床特徵和耐受性，這些都會影響處方行為。

深入分析美洲、歐洲、中東、非洲和亞太地區不同的醫療保健系統、報銷框架和就醫途徑。

區域趨勢顯著影響特發性肺纖維化（IPF）治療的臨床實踐模式、監管預期和商業性路徑，因此需要製定能夠反映各地區醫療體系結構和報銷環境的策略。在美洲，優秀醫療中心的集中以及保險公司與醫療服務提供者之間成熟的合作模式，使得指南推薦療法的推廣應用相對迅速。然而，都市區之間以及公立和私立保險公司在醫療服務取得方面仍然存在差異。同時，臨床網路和遠端醫療的普及正在改變患者從診斷到接受專科治療的流程。

主要企業層面洞察，整合了成熟企業在 IPF 治療方面的優勢、新興創新的發展軌跡以及管道和服務合作夥伴關係日益成長的重要性。

特發性肺纖維化（IPF）領域的競爭格局包括成熟的製藥公司、新興生物技術公司和專業經銷商，它們各自在臨床開發、商業化和患者支持方面擁有獨特的優勢。成熟的製藥公司在生產方面具有規模經濟效益，擁有豐富的全球監管經驗和廣泛的支付方網路，這使其能夠加快產品上市和醫保報銷談判。同時，新興生物技術公司通常開發差異化的作用機制和標靶聯合治療，以解決尚未明確的生物學通路，從而創造策略合作和授權的機會。

產業領導者在協調證據產生、供應鏈韌性、數位化醫療整合和區域市場進入規劃方面面臨的可操作策略挑戰

為了顯著改善特發性肺纖維化 (IPF) 患者的治療效果，產業領導者必須採取果斷行動，將臨床創新與永續的醫療服務取得和交付模式相結合。首先，應投資於產生可靠的實證醫學證據，將隨機對照試驗數據與真實世界的療效和安全性終點相結合，以支持與支付者的對話並更新臨床指南。在推動實證策略的同時，應建立靈活的供應鏈，制定短期緊急時應對計畫並實現供應商的策略多元化，以確保患者能夠穩定地獲得治療，同時降低關稅和地緣政治風險。

高度透明的多來源調查方法，結合了專家的直接訪談、臨床文獻的整合以及基於情境的供應鏈風險分析。

本報告的調查方法整合了多來源證據、對專科臨床醫生的訪談以及嚴謹的定性分析，以確保提供可靠的實踐見解。主要調查包括對呼吸科專家、臨床試驗專家、供應鏈經理和醫保報銷專家進行結構化訪談，以了解他們對診斷路徑、治療決定因素和營運瓶頸的實際觀點。次要調查則利用同儕審查文獻、監管指導文件、臨床指南和產品專論來檢驗臨床聲明和治療背景。

簡明結論強調了整合證據、營運韌性和相關人員合作的必要性：這些將把特發性肺纖維化 (IPF) 的創新與改善患者預後聯繫起來。

總之，特發性肺纖維化的治療格局正進入一個實踐創新階段，在治療方法的進步、醫療服務模式的演變以及貿易格局變化的推動下，治療的可及性和治療效果正在改變。對疾病機制和新型治療策略的深入理解為改變疾病進程提供了真正的契機，但要實現這一潛力，需要協調一致地投資於循證醫學、保障醫療資源供應以及以患者為中心的護理模式。積極將臨床開發與支付方需求和實際運作結合的相關人員，最能將科學進步轉化為病患的永續價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療分類分類的特發性肺纖維化市場

  • 抗纖維化藥物
    • 任天堂
    • Pirfenidone
  • 免疫抑制劑
    • 皮質類固醇
      • Methylprednisolone
      • 強的松
    • 免疫調節劑
      • Azathioprine
      • Mycophenolate Mofetil

第9章：特發性肺纖維化市場：依給藥途徑分類

  • 吸入
  • 注射藥物
  • 口服

第10章：特發性肺纖維化市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第11章：特發性肺纖維化市場：以最終用戶分類

  • 門診部
  • 家庭醫療保健設施
  • 醫院
  • 專科診所

第12章：特發性肺纖維化市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：特發性肺纖維化市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：特發性肺纖維化市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國特發性肺纖維化市場

第16章：中國特發性肺纖維化市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • GNI Group Ltd.
  • Horizon Therapeutics PLC by Amgen Inc.
  • Johnson & Johnson
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-2A0283E25610

The Idiopathic Pulmonary Fibrosis Market was valued at USD 4.19 billion in 2025 and is projected to grow to USD 4.42 billion in 2026, with a CAGR of 5.71%, reaching USD 6.19 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.19 billion
Estimated Year [2026] USD 4.42 billion
Forecast Year [2032] USD 6.19 billion
CAGR (%) 5.71%

A clinical and operational introduction to idiopathic pulmonary fibrosis highlighting diagnostic complexity, therapeutic progress, and evolving care pathways

Idiopathic pulmonary fibrosis (IPF) presents a persistent and complex clinical challenge that demands coordinated advances across diagnosis, therapeutics, and care delivery. Clinicians face hurdles in early identification because symptoms are often nonspecific and overlap with other chronic respiratory conditions, while diagnostic confirmation relies on high-resolution imaging, pulmonary function testing, and multidisciplinary consensus. These diagnostic realities delay initiation of disease-modifying therapies and complicate longitudinal management, increasing the imperative for clearer clinical pathways and improved access to diagnostic resources.

Concurrently, therapeutic evolution has introduced disease-modifying antifibrotics alongside legacy immunomodulatory approaches, reshaping clinical paradigms for slowing fibrosis progression and preserving lung function. Health systems now balance the clinical benefits of newer agents with considerations of tolerability, drug interactions, and long-term adherence. As stakeholders refine treatment algorithms, the field is witnessing greater emphasis on biomarkers, personalized risk stratification, and integrated care models that bridge hospital-based specialty clinics with ambulatory and home-based services. This shifting clinical landscape underscores the need for strategic alignment between clinical practice, product development, and payer engagement to optimize patient outcomes.

Transformative scientific, regulatory, and delivery-model shifts that are reshaping therapeutic development and care for idiopathic pulmonary fibrosis patients

The landscape for IPF care and therapy is undergoing transformative shifts driven by scientific, regulatory, and delivery-model forces. Advances in molecular biology and translational research have sharpened understanding of fibrogenic pathways, creating opportunities for novel mechanisms to complement or enhance existing antifibrotic strategies. At the same time, regulatory agencies are increasingly receptive to adaptive and real-world evidence approaches that shorten development timelines for agents with compelling mechanistic rationale, which in turn changes how sponsors prioritize assets and design pivotal programs.

On the delivery side, digital health tools and remote monitoring are moving from pilot projects into substantive components of chronic respiratory disease management. These technologies support earlier intervention, enable closer adherence monitoring, and facilitate value-based contracting discussions with payers. Additionally, shifts in reimbursement paradigms toward outcomes-based arrangements are incentivizing payers and providers to collaborate on adherence, adverse event mitigation, and optimized sequencing of therapies. Taken together, these forces are creating a more dynamic ecosystem where clinical innovation, regulatory flexibility, and commercial strategy must be tightly coordinated to realize therapeutic and health-economic value.

Comprehensive analysis of the projected cumulative effects of 2025 United States tariff adjustments on supply chains, pricing dynamics, and patient access in IPF care

Trade policy developments and tariff adjustments in 2025 present a complex backdrop for IPF supply chains, drug ingredient sourcing, and cross-border distribution of therapeutics and devices. Cumulative tariff measures can increase input costs for active pharmaceutical ingredients and excipients that are sourced globally, requiring manufacturers to reassess supplier portfolios and raw material procurement strategies. As a result, companies may pursue dual-sourcing, nearshoring, or vertical integration to preserve supply continuity and mitigate exposure to geopolitical volatility.

Beyond procurement, tariff-induced cost pressures can cascade into pricing negotiations and reimbursement dialogues. Payers and integrated delivery networks are likely to scrutinize cost drivers more closely, prompting manufacturers to provide robust value and outcomes data to support formulary positioning. In parallel, distribution partners and specialty pharmacies may adapt contracting structures to absorb or pass through cost increases, influencing patient access pathways and adherence programs. Therefore, firms operating in the IPF space should evaluate tariff scenarios within their commercial risk frameworks, stress test supply chain resilience, and proactively engage stakeholders to preserve uninterrupted patient access to essential therapies.

In-depth segmentation perspective synthesizing therapeutic class, administration route, distribution channel, and care setting distinctions that drive commercial and clinical strategy

Segment-level differentiation underpins strategic decision-making for IPF stakeholders, requiring nuanced understanding of therapeutic classes, administration routes, distribution networks, and end-user settings. Based on therapeutic class, the landscape is studied across Antifibrotics and Immunosuppressants, with Antifibrotics further distinguished by Nintedanib and Pirfenidone and Immunosuppressants further subdivided into Corticosteroids and Immunomodulators; the Corticosteroids segment includes Methylprednisolone and Prednisone while Immunomodulators include Azathioprine and Mycophenolate Mofetil, each presenting distinct clinical profiles and tolerability considerations that influence prescribing behavior.

Route of administration considerations separate inhalation, injectable, and oral modalities, which in turn affect adherence patterns, monitoring requirements, and outpatient versus inpatient utilization. Distribution channel dynamics encompass Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Pharmacies, shaping how therapies are dispensed and what support services accompany treatment initiation and maintenance. End-user segmentation spans Ambulatory Care Centers, Home Healthcare Facilities, Hospitals, and Specialty Clinics, each with varied capacity for diagnostics, pulmonary rehabilitation, and complex therapy management. Integrating these segmentation lenses enables stakeholders to identify where clinical need, commercial opportunity, and operational friction intersect, and to prioritize interventions that reduce patient burden while improving therapeutic outcomes.

Detailed regional insights that reconcile differing healthcare systems, reimbursement frameworks, and access pathways across the Americas, Europe Middle East & Africa and Asia-Pacific

Regional dynamics significantly influence clinical practice patterns, regulatory expectations, and commercial pathways for IPF therapies, requiring strategies that reflect local healthcare system structures and reimbursement environments. In the Americas, concentrated centers of excellence and integrated payer-provider models support relatively rapid uptake of guideline-endorsed therapies, yet access variability persists across urban and rural settings and between public and private payers. Meanwhile, clinical networks and telehealth diffusion are changing how patients navigate from diagnosis to specialty care.

In Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement systems create a mosaic of pricing and access conditions that necessitate differentiated market entry strategies and localized evidence generation. Stakeholders often prioritize health technology assessment alignment and real-world data collection to support country-specific value dossiers. Across Asia-Pacific, rapid healthcare modernization, growing specialty care capacity, and evolving domestic manufacturing capabilities are reshaping supply chains and commercial models, while variable affordability considerations and differing clinical guideline adoption timelines require tailored engagement with local clinicians and payers. Appreciating these regional nuances is essential for developing implementation plans that respect local standards of care and maximize patient access.

Key company-level insights synthesizing incumbent advantages, emergent innovation trajectories, and the rising importance of channel and service partnerships in IPF care

The competitive landscape for IPF encompasses established pharmaceutical sponsors, emerging biotechs, and specialty distributors, each contributing distinct capabilities across clinical development, commercialization, and patient support. Established companies bring scale in manufacturing, global regulatory experience, and broad payer relationships that can accelerate product rollout and reimbursement negotiations. Emerging biotechs, by contrast, often advance differentiated mechanisms or targeted combinations that may address unmet biological pathways and create opportunities for strategic partnerships or licensing transactions.

Channel and service providers such as specialty pharmacies and patient support vendors are increasingly strategic partners, delivering adherence programs, infusion coordination, and outcomes tracking that influence long-term treatment success. Contract research organizations and real-world evidence partners also play critical roles by enabling pragmatic studies and post-approval data collection. As competitive dynamics evolve, successful companies will integrate clinical evidence generation with commercial planning, leverage partnerships to bridge capability gaps, and maintain flexibility to respond to payer feedback and new clinical insights.

Actionable strategic imperatives for industry leaders to synchronize evidence generation, supply resilience, digital care integration, and localized market access planning

Industry leaders must act decisively to align clinical innovation with sustainable access and delivery models if they are to meaningfully improve outcomes for people living with IPF. First, invest in robust evidence generation that pairs randomized controlled data with real-world effectiveness and safety endpoints to support payer dialogues and clinical guideline updates. Complementary to evidence strategy, build flexible supply chains with near-term contingency plans and strategic supplier diversification to mitigate tariff and geopolitical risk while preserving consistent patient access.

Operationally, integrate digital monitoring and remote care capabilities into commercial offerings to support adherence, early adverse event detection, and longitudinal outcomes measurement. Collaborate with specialty pharmacies and home healthcare providers to streamline initiation processes and reduce administrative burden on clinicians. Finally, develop localized market access plans that align value communication with country-specific health technology assessment requirements and engage early with clinical opinion leaders to accelerate guideline adoption. By executing these priorities, leaders can translate scientific progress into tangible improvements in care delivery and patient experience.

Transparent, multi-source research methodology combining expert primary interviews, clinical literature synthesis, and scenario-driven supply chain risk analysis

The research methodology underpinning this report integrates multi-source evidence synthesis, expert clinician interviews, and rigorous qualitative analysis to ensure robust and actionable findings. Primary research included structured interviews with pulmonologists, clinical trial specialists, supply chain managers, and reimbursement experts to capture frontline perspectives on diagnostic pathways, therapeutic decision drivers, and operational bottlenecks. Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical guidelines, and product monographs to validate clinical assertions and therapeutic context.

Analytic methods combined thematic coding of qualitative inputs with comparative assessments of treatment paradigms and distribution channel practices. Scenario analysis was employed to evaluate supply chain exposures and tariff-related risks, while stakeholder mapping informed recommendations on payer engagement and partnership prioritization. Throughout, the approach emphasized triangulation of evidence and transparent documentation of assumptions to support confident decision-making by clinical, commercial, and policy audiences.

Concise conclusion emphasizing the necessity of integrated evidence, operational resilience, and stakeholder collaboration to translate IPF innovations into improved patient outcomes

In conclusion, the idiopathic pulmonary fibrosis landscape is entering a period of pragmatic innovation where therapeutic advances, evolving care delivery models, and shifting trade dynamics converge to redefine access and outcomes. Improved mechanistic understanding and novel therapeutic strategies present genuine opportunities to alter disease trajectories, but realizing that potential demands coordinated investments in evidence, supply resilience, and patient-centric care models. Stakeholders who proactively align clinical development with payer needs and operational realities will be best positioned to translate scientific progress into durable value for patients.

As the ecosystem continues to evolve, continual engagement with clinicians, payers, and service providers will be essential to refine treatment algorithms, optimize adherence support, and ensure equitable access. The pathway forward requires both scientific rigor and pragmatic commercial execution, with a relentless focus on measurable improvements in lung function, quality of life, and system-level efficiencies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Idiopathic Pulmonary Fibrosis Market, by Therapeutic Class

  • 8.1. Antifibrotics
    • 8.1.1. Nintedanib
    • 8.1.2. Pirfenidone
  • 8.2. Immunosuppressants
    • 8.2.1. Corticosteroids
      • 8.2.1.1. Methylprednisolone
      • 8.2.1.2. Prednisone
    • 8.2.2. Immunomodulators
      • 8.2.2.1. Azathioprine
      • 8.2.2.2. Mycophenolate Mofetil

9. Idiopathic Pulmonary Fibrosis Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral

10. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Specialty Pharmacies

11. Idiopathic Pulmonary Fibrosis Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Healthcare Facilities
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Idiopathic Pulmonary Fibrosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Idiopathic Pulmonary Fibrosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Idiopathic Pulmonary Fibrosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Idiopathic Pulmonary Fibrosis Market

16. China Idiopathic Pulmonary Fibrosis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AstraZeneca PLC
  • 17.6. Boehringer Ingelheim International GmbH
  • 17.7. Bristol-Myers Squibb Company
  • 17.8. F. Hoffmann-La Roche Ltd.
  • 17.9. Galapagos NV
  • 17.10. Gilead Sciences, Inc.
  • 17.11. Glenmark Pharmaceuticals Ltd.
  • 17.12. GNI Group Ltd.
  • 17.13. Horizon Therapeutics PLC by Amgen Inc.
  • 17.14. Johnson & Johnson
  • 17.15. Lupin Ltd.
  • 17.16. Merck & Co., Inc.
  • 17.17. Novartis AG
  • 17.18. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)